アンジオテンシン変換酵素阻害剤とアンジオテンシン受容体阻害剤の比較効果: マルチデータベース標的試験エミュレーション研究
Chao Xie1,2, Ruixuan Chen1, Shiyu Zhou1
1Division of Nephrology, Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease; State Key Laboratory of Organ Failure Research; Guangdong Provincial Institute of Nephrology; Guangdong Provincial Key Laboratory of Renal Failure Research, China (C.X., R.C., S.Z., Y.L., J.L., L.S., M.P., Z.G., F.L., S.N.).
Hypertension (Dallas, Tex. : 1979)
|September 4, 2025
まとめ
アンジオテンシン変換酵素 (ACE) 阻害剤は,アンジオテンシン受容体阻害剤 (ARB) と比較して,死亡のリスクや主要な心血管不良の増加と関連していました. 肝心な心臓血管と腎臓の 保護薬の厳選が不可欠であることを示唆しています
科学分野:
- 心血管医学
- 薬理学について
- 腎臓科
背景:
- 血管系および腎臓の保護のために,アニオテンシン変換酵素 (ACE) 阻害剤およびアニオテンシン受容体阻害剤 (ARB) が推奨されます.
- 死亡率に関するACE阻害剤とARBの長期的な効果の比較は十分に確立されていません.
研究 の 目的:
- すべての原因による死亡率と主要な心血管不良症候群におけるACE阻害剤とARBの長期的有効性を比較する.
- アンジオテンシン・アルドステロン系阻害剤の最適な選択のための証拠を提供するために.
主な方法:
- イギリスのバイオバンクと中国の腎臓データシステムを用いたマルチデータベースコホート研究.
- ACE阻害剤またはARBの新規使用者に対する傾向スコアをマッチングした標的試験エミュレーションフレームワーク.
- 主要アウトカム: 5年全因死亡率 二次的アウトカム: 主要な心血管疾患
主要な成果:
- ACE阻害剤の投与開始は,全原因で5年後に死亡するリスクが高かった (英国バイオバンク: HR1. 13;中国腎臓データシステム: HR1. 12).
- 両方のデータベースでは,ARBイニシアターと比較して,ACE阻害剤を投与開始した患者は,重大な心血管疾患のリスクがより高かった.
- 両方の大規模なデータベースで一致する結果は,研究の結論を強化します.
結論:
- ACE阻害薬の投与開始は,ARBと比較して,全因死亡率と主要な心血管疾患のリスクが高いことが示された.
- 研究結果は,患者のケアのためにACE阻害剤とARBを選択する際の慎重な検討の必要性を強調しています.
- この研究は,これらの広く使用されている薬物の安全性と有効性の比較に関する貴重な洞察をもたらします.
さらに関連する動画
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:25Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
910
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
910
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
869
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
869
01:22Dose-Response Relationship: Potency and Efficacy
5.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.1K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
250
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
250